Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer

Abstract

Zenocutuzumab showed efficacy in patients with advanced <i>NRG1</i> fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).